Harvard Bioscience Inc.
HBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.02M
Close$
$-3.08
146.2% downside
Current Fair Value
146.2% downsideOvervalued by 146.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.02 Million |
|---|---|
| Enterprise Value | $71.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.8 |
| Beta | 1.49 |
| Outstanding Shares | 4,526,000 |
Return
| Return on Equity | -140.36% |
|---|---|
| Return on Assets | -13.65% |
| Return on Invested Capital | 97.04% |
Valuation & Multiples
| P/E Ratio | -2.86 |
|---|---|
| PEG | -10.4 |
| Price to Sales | 0.35 |
| Price to Book Ratio | 6.67 |
| Enterprise Value to Revenue | 0.81 |
| Enterprise Value to EBIT | 1.43 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.67 |
| Debt to Equity | 6.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$21.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$21.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 35.45%▼ 3.88% |
|---|---|
| Total Invested | $7.73M▼ 33.84% |
| Investors Holding | 36▼ 28.00% |
ESG Score
No data